CEPORACIN 1 G — DIN 02060051
CEPHALOTHIN (CEPHALOTHIN SODIUM) : 1 G · MYLAN PHARMACEUTICALS ULC · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is CEPORACIN?
CEPORACIN 1 G contains CEPHALOTHIN (CEPHALOTHIN SODIUM) : 1 G. It is listed in the Health Canada Drug Product Database under DIN 02060051, held by MYLAN PHARMACEUTICALS ULC, supplied as POWDER FOR SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 03-Nov-2015. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is CEPORACIN used for?
Serious infections (respiratory, skin, GU, septicemia, meningitis, bone/joint) caused by susceptible strains. Perioperative prophylaxis to reduce postoperative infections.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Cefalotin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
2 holders have a Canadian DIN containing Cefalotin, across 4 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| ELI LILLY CANADA INC | 3 | 0 | KEFLIN ADD-VANTAGE INJ 1GM/VIAL, KEFLIN NEUTRAL INJ 1GM, KEFLIN NEUTRAL INJ 2GM/VIAL | No marketed DIN |
| MYLAN PHARMACEUTICALS ULC | 1 | 0 | CEPORACIN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 1 G |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAMUSCULAR ; INTRAVENOUS |
| Pack configuration (monograph) | 1 g vials containing cephalothin sodium and sodium bicarbonate buffer. |
| Storage | Reconstituted: 24h at room temperature or 72h refrigerated. Bacteriostatic I.M. solutions: 7 days refrigerated. Replace I.V. infusions every 24h. Do not use dark brown solutions. |
| Shipping class | Cold chain — validated shipper with temperature monitoring |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Cefalotin |
|---|---|
| ATC code | J01DB03 |
| AHFS class | 08:12.06.04 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02060051 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2060051 |
| Brand name | CEPORACIN |
| Generic / active ingredient | CEPHALOTHIN (CEPHALOTHIN SODIUM) : 1 G |
| Market authorization holder | MYLAN PHARMACEUTICALS ULC |
| Health Canada schedule | Prescription |
| ATC code | J01DB03 |
| ATC anatomical main group | J — Anti-infectives for systemic use |
| ATC therapeutic subgroup | J01DB |
| Current status | CANCELLED POST MARKET |
| Status date | 03-Nov-2015 |
| Original market date | 1994-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 500 mg to 2 g every 4 to 6 hours. Life-threatening: up to 2 g every 4 hours. Children: 80 to 160 mg/kg/day in divided doses. Administer via I.M., I.V. (bolus or infusion), or intraperitoneal.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Contraindicated in persons hypersensitive to the cephalosporins.
Warnings and precautions
Inquire about penicillin/cephalosporin allergy (cross-allergenicity risk). Pseudomembranous colitis risk. High I.V. doses (>6g/day) may cause thrombophlebitis. Seizure risk in renal impairment.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 4 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| KEFLIN ADD-VANTAGE INJ 1GM/VIAL | 1 G | LIQUID | ELI LILLY CANADA INC | CANCELLED POST MARKET | 00752525 |
| KEFLIN NEUTRAL INJ 1GM | 1 G | POWDER FOR SOLUTION | ELI LILLY CANADA INC | CANCELLED POST MARKET | 00015369 |
| KEFLIN NEUTRAL INJ 2GM/VIAL | 2 G | POWDER FOR SOLUTION | ELI LILLY CANADA INC | CANCELLED POST MARKET | 00244406 |
2 · Same class — other molecules in ATC J01DB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Cefalexin | APO-CEPHALEX · ASN-CEPHALEXIN · AURO-CEPHALEXIN · CEPHALEXIN · +25 more | 47 | 23 | Yes |
| Cefazolin | ANCEF INJ PWS 10GM/VIAL USP · ANCEF INJ PWS 1GM/VIAL USP · ANCEF INJ PWS 500MG/VIAL USP · CEFAZOLIN FOR INJECTION · +8 more | 34 | 15 | Yes |
| Cefadroxil | APO-CEFADROXIL · CEFADROXIL · DURICEF · JAMP CEFADROXIL · +2 more | 6 | 3 | Yes |
| Cefalotin | CEPORACIN · KEFLIN ADD-VANTAGE INJ 1GM/VIAL · KEFLIN NEUTRAL INJ 1GM · KEFLIN NEUTRAL INJ 2GM/VIAL | 4 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC J01D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| J01DD | Cefixime · Cefotaxime · Cefpodoxime · Ceftazidime · Ceftizoxime · +1 more | 96 | 25 |
| J01DH | Doripenem · Ertapenem · Imipenem And Cilastatin · Meropenem · Meropenem And Vaborbactam | 51 | 24 |
| J01DC | Cefaclor · Cefamandole · Cefotetan · Cefoxitin · Cefprozil · +1 more | 135 | 18 |
| J01DE | Cefepime | 10 | 3 |
| J01DF | Aztreonam | 1 | 1 |
| J01DI | Ceftobiprole Medocaril · Ceftolozane And Beta-Lactamase Inhibitor | 2 | 1 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.